Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities.
biomarkers
cachexia
incidence
mortality
pancreatic cancer
racial disparities
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
21
11
2018
revised:
29
03
2019
accepted:
03
04
2019
pubmed:
11
5
2019
medline:
8
7
2020
entrez:
11
5
2019
Statut:
ppublish
Résumé
Pancreatic cancer (PC) is characterized by racial/ethnic disparities and the debilitating muscle-wasting condition, cancer cachexia. Florida ranks second in the number of PC deaths and has a large and understudied minority population. We examined the primary hypothesis that PC incidence and mortality rates may be highest among Black Floridians and the secondary hypothesis that biological correlates of cancer cachexia may underlie disparities. PC incidence and mortality rates were estimated by race/ethnicity, gender, and county using publicly available state-wide cancer registry data that included approximately 2700 Black, 25 200 Non-Hispanic White (NHW), and 3300 Hispanic/Latino (H/L) Floridians diagnosed between 2004 and 2014. Blacks within Florida experienced a significantly (P < 0.05) higher incidence (12.5/100 000) and mortality (10.97/100 000) compared to NHW (incidence = 11.2/100 000; mortality = 10.3/100 000) and H/L (incidence = 9.6/100 000; mortality = 8.7/100 000), especially in rural counties. To investigate radiologic and blood-based correlates of cachexia, we leveraged data from a subset of patients evaluated at two geographically distinct Florida Cancer Centers. In Blacks compared to NHW matched on stage, markers of PC-induced cachexia were more frequent and included greater decreases in core musculature compared to corresponding healthy control patients (25.0% vs 10.1% lower), greater decreases in psoas musculature over time (10.5% vs 4.8% loss), lower baseline serum albumin levels (3.8 vs 4.0 gm/dL), and higher platelet counts (332.8 vs 268.7 k/UL). Together, these findings suggest for the first time that PC and cachexia may affect Blacks disproportionately. Given its nearly universal contribution to illness and PC-related deaths, the early diagnosis and treatment of cachexia may represent an avenue to improve health equity, quality of life, and survival.
Identifiants
pubmed: 31074202
doi: 10.1002/cam4.2180
pmc: PMC6558500
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
3314-3324Subventions
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Anticancer Res. 2017 Feb;37(2):787-793
pubmed: 28179331
Oncologist. 2019 May;24(5):691-701
pubmed: 30591550
Ann Surg Oncol. 2013 Jun;20(6):2078-87
pubmed: 23579872
Br J Surg. 2019 Mar;106(4):342-354
pubmed: 30758855
Pancreas. 2019 Feb;48(2):242-249
pubmed: 30629027
J Appl Physiol (1985). 1998 Jul;85(1):115-22
pubmed: 9655763
J Thromb Haemost. 2017 Mar;15(3):477-486
pubmed: 28058802
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Exp Ther Med. 2012 Mar;3(3):423-432
pubmed: 22969906
J Gastrointest Oncol. 2018 Feb;9(1):17-23
pubmed: 29564167
Ann Surg. 1998 Sep;228(3):429-38
pubmed: 9742926
J Am Coll Surg. 2009 Dec;209(6):720-6
pubmed: 19959040
J Cachexia Sarcopenia Muscle. 2019 Apr;10(2):368-377
pubmed: 30719874
Cancer Med. 2019 Jun;8(6):3314-3324
pubmed: 31074202
Epidemiology. 2003 Jan;14(1):45-54
pubmed: 12500045
Am J Surg. 2017 Nov;214(5):862-870
pubmed: 28760357
Am J Surg. 2019 Apr;217(4):725-731
pubmed: 30583797
Cancer. 2009 Sep 1;115(17):3979-90
pubmed: 19514091
Curr Treat Options Oncol. 2010 Dec;11(3-4):107-17
pubmed: 21128029
Oncotarget. 2017 Jan 3;8(1):1177-1189
pubmed: 27901481
Cancer Metastasis Rev. 2017 Jun;36(2):199-213
pubmed: 28730545
Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2397-405
pubmed: 19723915
Int J Mol Sci. 2018 Dec 01;19(12):
pubmed: 30513792
J Clin Oncol. 2015 Jun 20;33(18):2028-34
pubmed: 25987694
Future Oncol. 2016;12(8):997-1000
pubmed: 26863203
World J Gastrointest Surg. 2018 Dec 27;10(9):95-106
pubmed: 30622678
J Gastrointest Surg. 2015 Sep;19(9):1593-602
pubmed: 25925237
Crit Rev Oncol Hematol. 2011 Oct;80(1):114-44
pubmed: 21216616
Am J Med Sci. 2015 Oct;350(4):250-6
pubmed: 26083652
J Cachexia Sarcopenia Muscle. 2013 Sep;4(3):179-86
pubmed: 23532635
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Ann Surg Oncol. 2009 Nov;16(11):2968-77
pubmed: 19669839
Pancreas. 2018 Feb;47(2):221-226
pubmed: 29329156
J Clin Med. 2018 Dec 01;7(12):
pubmed: 30513776
Cancer. 2005 Jan 15;103(2):349-57
pubmed: 15593353
Ann Surg Oncol. 2012 Sep;19(9):2776-81
pubmed: 22526908
Surgery. 2017 Apr;161(4):930-938
pubmed: 27932030
Cancers (Basel). 2018 Jul 18;10(7):
pubmed: 30021952
Pancreas. 2015 May;44(4):522-7
pubmed: 25872128
Support Care Cancer. 2013 Jun;21(6):1569-77
pubmed: 23314651
Platelets. 2018 Jun 4;:1-7
pubmed: 29863945
Front Physiol. 2014 Mar 03;5:88
pubmed: 24624094
Nutr J. 2010 Dec 22;9:69
pubmed: 21176210
Nutrients. 2017 Mar 07;9(3):
pubmed: 28272344
J Cachexia Sarcopenia Muscle. 2011 Mar;2(1):1-3
pubmed: 21475620
J Am Coll Surg. 2008 Apr;206(4):622.e1-9
pubmed: 18387466
Curr Opin Clin Nutr Metab Care. 2016 May;19(3):188-98
pubmed: 26945342
Front Physiol. 2014 Jul 07;5:250
pubmed: 25071595
Eur J Radiol. 2016 Aug;85(8):1461-8
pubmed: 26971404
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):546-52
pubmed: 17372250